Kidney glycosphingolipids are elevated early in diabetic nephropathy and mediate hypertrophy of mesangial cells

American Journal of Physiology - Renal Physiology

Volumn 309, Issue 3, 2015, Pages F204-F215

  Subathra, Marimuthu ^a   Korrapati, Midhun ^b   Howell, Lauren A ^c   Arthur, John M ^d,e   Shayman, James A ^f   Schnellmann, Rick G ^b,g   Siskind, Leah J ^a  

^a University of Louisville School of Medicine   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c FLORIDA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Diabetic nephropathy; Glycosphingolipids; Hypertrophy; Kidney; Mesangial cells

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE; CERAMIDE TRIHEXOSIDE; GALACTOSYLCERAMIDE; GLUCOSE; GLUCOSYLCERAMIDE; GLYCOSPHINGOLIPID; LACTOSYLCERAMIDE; SCLEROPROTEIN; CDW17 ANTIGEN; LEUKOCYTE ANTIGEN; ONCOPROTEIN; SMAD3 PROTEIN; SMAD3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FEMALE; GLOMERULUS; HYPERGLYCEMIA; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; URINE; ANIMAL; CELL LINE; EXPERIMENTAL DIABETES MELLITUS; HUMAN; KIDNEY; KIDNEY PROXIMAL TUBULE; MESANGIUM CELL; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; ULTRASTRUCTURE;

ANIMALS; ANTIGENS, CD; CELL LINE; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GLYCOSPHINGOLIPIDS; HUMANS; KIDNEY; KIDNEY GLOMERULUS; KIDNEY TUBULES, PROXIMAL; LACTOSYLCERAMIDES; MESANGIAL CELLS; MICE; ONCOGENE PROTEIN V-AKT; SIGNAL TRANSDUCTION; SMAD3 PROTEIN;

EID: 84938598950     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00150.2015     Document Type: Article

References (65)

1. Aerts JM, Ottenhoff R, Powlson AS, Grefhorst A, van Eijk M, Dubbelhuis PF, Aten J, Kuipers F, Serlie MJ, Wennekes T, Sethi JK, O'Rahilly S, Overkleeft HS. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 56: 1341-1349, 2007.
2. Baccora MH, Cortes P, Hassett C, Taube DW, Yee J. Effects of long-term elevated glucose on collagen formation by mesangial cells. Kidney Int 72: 1216-1225, 2007.
3. Bielawski J, Szulc ZM, Hannun YA, Bielawska A. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 39: 82-91, 2006.
4. Caseiro A, Barros A, Ferreira R, Padrao A, Aroso M, Quintaneiro C, Pereira A, Marinheiro R, Vitorino R, Amado F. Pursuing type 1 diabetes mellitus and related complications through urinary proteomics. Transl Res 163: 188-199, 2014.
5. Chae YM, Park KK, Magae J, Lee IS, Kim CH, Kim HC, Hong S, Lee JG, Choi IJ, Kim HS, Min KS, Lee IK, Chang YC. Sp1-decoy oligodeoxynucleotide inhibits high glucose-induced mesangial cell proliferation. Biochem Biophys Res Commun 319: 550-555, 2004.
6. Chatterjee S, Shi WY, Wilson P, Mazumdar A. Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease. J Lipid Res 37: 1334-1344, 1996.
7. Chatterjee S, Wei H. Roles of glycosphingolipids in cell signaling: adhesion, migration, and proliferation. Methods Enzymol 363: 300-312, 2003.
8. Covington MD, Schnellmann RG. Chronic high glucose downregulates mitochondrial calpain 10 and contributes to renal cell death and diabetesinduced renal injury. Kidney Int 81: 391-400, 2012.
9. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355: 1481-1485, 2000.
10. Das F, Dey N, Venkatesan B, Kasinath BS, Ghosh-Choudhury N, Choudhury GG. High glucose upregulation of early-onset Parkinson's disease protein DJ-1 integrates the PRAS40/TORC1 axis to mesangial cell hypertrophy. Cell Signal 23: 1311-1319, 2011.
11. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61: 939-950, 2002.
12. Degroote S, Wolthoorn J, van Meer G. The cell biology of glycosphingolipids. Semin Cell Dev Biol 15: 375-387, 2004.
13. Foley RN, Collins AJ. The growing economic burden of diabetic kidney disease. Curr Diabetes Rep 9: 460-465, 2009.
14. Forbes JM, Fukami K, Cooper ME. Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 115: 69-84, 2007.
15. Fujimoto M, Maezawa Y, Yokote K, Joh K, Kobayashi K, Kawamura H, Nishimura M, Roberts AB, Saito Y, Mori S. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem Biophys Res Commun 305: 1002-1007, 2003.
16. Grove KJ, Voziyan PA, Spraggins JM, Wang S, Paueksakon P, Harris RC, Hudson BG, Caprioli RM. Diabetic nephropathy induces alterations in the glomerular and tubule lipid profiles. J Lipid Res 55: 1375-1385, 2014.
17. Gruden G, Perin PC, Camussi G. Insight on the pathogenesis of diabetic nephropathy from the study of podocyte and mesangial cell biology. Curr Diabetes Rev 1: 27-40, 2005.
18. +/glucose cotransporter activity in renal proximal tubule cells. Am J Physiol Renal Physiol 288: F988-F996, 2005.
19. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 96: 1802-1814, 1995.
20. Hickey FB, Martin F. Diabetic kidney disease and immune modulation. Curr Opin Pharmacol 13: 602-612, 2013.
21. Higgins GC, Coughlan MT. Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy? Br J Pharmacol 171: 1917-1942, 2014.
22. Isono M, Chen S, Hong SW, de la Iglesias-Cruz MC, Ziyadeh FN. Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-β-induced fibronectin in mesangial cells. Biochem Biophys Res Commun 296: 1356-1365, 2002.
23. Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S, Danesh FR. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med 233: 4-11, 2008.
24. Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I, Gunn A, Nakagawa Y, Shimano H, Todorov I, Rossi JJ, Natarajan R. TGF-β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 11: 881-889, 2009.
25. Korrapati MC, Howell LH, Shaner BE, Megyesi JK, Siskind LJ, Schnellmann RG. Suramin: a potential therapy for diabetic nephropathy. PLos One 8: e73655, 2013.
26. Lahiri S, Futerman AH. The metabolism and function of sphingolipids and glycosphingolipids. Cell Mol Life Sci 64: 2270-2284, 2007.
27. Langeveld M, Aerts JM. Glycosphingolipids and insulin resistance. Prog Lipid Res 48: 196-205, 2009.
28. Lee L, Abe A, Shayman JA. Improved inhibitors of glucosylceramide synthase. J Biol Chem 274: 14662-14669, 1999.
29. Lehmann R, Schleicher ED. Molecular mechanism of diabetic nephropathy. Clin Chim Acta 297: 135-144, 2000.
30. Liu L, Hu X, Cai GY, Lv Y, Zhuo L, Gao JJ, Cui SY, Feng Z, Fu B, Chen XM. High glucose-induced hypertrophy of mesangial cells is reversed by connexin43 overexpression via PTEN/Akt/mTOR signaling. Nephrol Dial Transplant 27: 90-100, 2012.
31. Lukina E, Watman N, Dragosky M, Pastores GM, Arreguin EA, Rosenbaum H, Zimran A, Angell J, Ross L, Puga AC, Peterschmitt JM. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis 53: 274-276, 2014.
32. Mahimainathan L, Das F, Venkatesan B, Choudhury GG. Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes 55: 2115-2125, 2006.
33. Marshall J, Ashe KM, Bangari D, McEachern K, Chuang WL, Pacheco J, Copeland DP, Desnick RJ, Shayman JA, Scheule RK, Cheng SH. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLos One 5: e15033, 2010.
34. Masson E, Lagarde M, Wiernsperger N, El Bawab S. Hyperglycemia and glucosamine-induced mesangial cell cycle arrest and hypertrophy: Common or independent mechanisms? IUBMB Life 58: 381-388, 2006.
35. Mather AR, Siskind LJ. Glycosphingolipids and kidney disease. Adv Exp Med Biol 721: 121-138, 2011.
36. McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, Hutto E, Shayman JA, Grabowski GA, Aerts JM, Cheng SH, Copeland DP, Marshall J. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 91: 259-267, 2007.
37. Miller CG, Pozzi A, Zent R, Schwarzbauer JE. Effects of high glucose on integrin activity and fibronectin matrix assembly by mesangial cells. Mol Biol Cell 25: 2342-2350, 2014.
38. Morales A, Colell A, Mari M, Garcia-Ruiz C, Fernandez-Checa JC. Glycosphingolipids and mitochondria: role in apoptosis and disease. Glycoconj J 20: 579-588, 2004.
39. Nahman NS Jr, Leonhart KL, Cosio FG, Hebert CL. Effects of high glucose on cellular proliferation and fibronectin production by cultured human mesangial cells. Kidney Int 41: 396-402, 1992.
40. Natoli TA, Smith LA, Rogers KA, Wang B, Komarnitsky S, Budman Y, Belenky A, Bukanov NO, Dackowski WR, Husson H, Russo RJ, Shayman JA, Ledbetter SR, Leonard JP, Ibraghimov-Beskrovnaya O. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med 16: 788-792, 2010.
41. Nowling TK, Mather AR, Thiyagarajan T, Hernandez-Corbacho MJ, Powers TW, Jones EE, Snider AJ, Oates JC, Drake RR, Siskind LJ. Renal glycosphingolipid metabolism is dysfunctional in lupus nephritis. J Am Soc Nephrol 26: 1402-1413, 2015.
42. Petermann AT, Pippin J, Durvasula R, Pichler R, Hiromura K, Monkawa T, Couser WG, Shankland SJ. Mechanical stretch induces podocyte hypertrophy in vitro. Kidney Int 67: 157-166, 2005.
43. Peterschmitt MJ, Burke A, Blankstein L, Smith SE, Puga AC, Kramer WG, Harris JA, Mathews D, Bonate PL. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol 51: 695-705, 2011.
44. Phillips AO, Baboolal K, Riley S, Grone H, Janssen U, Steadman R, Williams J, Floege J. Association of prolonged hyperglycemia with glomerular hypertrophy and renal basement membrane thickening in the Goto Kakizaki model of non-insulin-dependent diabetes mellitus. Am J Kidney Dis 37: 400-410, 2001.
45. Qureshi A, Subathra M, Grey A, Schey K, Del Poeta M, Luberto C. Role of sphingomyelin synthase in controlling the antimicrobial activity of neutrophils against Cryptococcus neoformans. PLos One 5: e15587, 2010.
46. Shen W, Henry AG, Paumier KL, Li L, Mou K, Dunlop J, Berger Z, Hirst WD. Inhibition of glucosylceramide synthase stimulates autophagy flux in neurons. J Neurochem 129: 884-894, 2014.
47. Stathem M, Marimuthu S, O'Neal J, Rathmell JC, Chesney JA, Beverly LJ, Siskind LJ. Glucose availability and glycolytic metabolism dictate glycosphingolipid levels. J Cell Biochem 116: 67-80, 2015.
48. Sugimoto H, Grahovac G, Zeisberg M, Kalluri R. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 56: 1825-1833, 2007.
49. Tahara A, Tsukada J, Tomura Y, Yatsu T, Shibasaki M. Effects of high glucose on AVP-induced hyperplasia, hypertrophy, and type IV collagen synthesis in cultured rat mesangial cells. Endocr Res 37: 216- 227, 2012.
50. Tanimoto M, Gohda T, Kaneko S, Hagiwara S, Murakoshi M, Aoki T, Yamada K, Ito T, Matsumoto M, Horikoshi S, Tomino Y. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism 56: 160-167, 2007.
51. Uttarwar L, Gao B, Ingram AJ, Krepinsky JC. SREBP-1 activation by glucose mediates TGF-β upregulation in mesangial cells. Am J Physiol Renal Physiol 302: F329-F341, 2012.
52. Vunnam RR, Radin NS. Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain. Chem Phys Lipids 26: 265-278, 1980.
53. Wang A, Ziyadeh FN, Lee EY, Pyagay PE, Sung SH, Sheardown SA, Laping NJ, Chen S. Interference with TGF-β signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am J Physiol Renal Physiol 293: F1657-F1665, 2007.
54. Wang Y, Heilig K, Saunders T, Minto A, Deb DK, Chang A, Brosius F, Monteiro C, Heilig CW. Transgenic overexpression of GLUT1 in mouse glomeruli produces renal disease resembling diabetic glomerulosclerosis. Am J Physiol Renal Physiol 299: F99-F111, 2010.
55. Wennekes T, van den Berg RJ, Boot RG, van der Marel GA, Overkleeft HS, Aerts JM. Glycosphingolipids-nature, function, and pharmacological modulation. Angew Chem Int Ed Engl 48: 8848-8869, 2009.
56. Whitfield PD, Calvin J, Hogg S, O'Driscoll E, Halsall D, Burling K, Maguire G, Wright N, Cox TM, Meikle PJ, Deegan PB. Monitoring enzyme replacement therapy in Fabry disease-role of urine globotriaosylceramide. J Inherit Metab Dis 28: 21-33, 2005.
57. Wu D, Peng F, Zhang B, Ingram AJ, Kelly DJ, Gilbert RE, Gao B, Krepinsky JC. PKC-β1 mediates glucose-induced Akt activation and TGF-β1 upregulation in mesangial cells. J Am Soc Nephrol 20: 554-566, 2009.
58. Wu D, Peng F, Zhang B, Ingram AJ, Kelly DJ, Gilbert RE, Gao B, Kumar S, Krepinsky JC. EGFR-PLCγ1 signaling mediates high glucose- induced PKCβ1-Akt activation and collagen I upregulation in mesangial cells. Am J Physiol Renal Physiol 297: F822-F834, 2009.
59. Yamashita T, Hashiramoto A, Haluzik M, Mizukami H, Beck S, Norton A, Kono M, Tsuji S, Daniotti JL, Werth N, Sandhoff R, Sandhoff K, Proia RL. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci USA 100: 3445-3449, 2003.
60. Yuan P, Xue H, Zhou L, Qu L, Li C, Wang Z, Ni J, Yu C, Yao T, Huang Y, Wang R, Lu L. Rescue of mesangial cells from high glucoseinduced over-proliferation and extracellular matrix secretion by hydrogen sulfide. Nephrol Dial Transplant 26: 2119-2126, 2011.
61. Zador IZ, Deshmukh GD, Kunkel R, Johnson K, Radin NS, Shayman JA. A role for glycosphingolipid accumulation in the renal hypertrophy of streptozotocin-induced diabetes mellitus. J Clin Invest 91: 797-803, 1993.
62. Zhang L, Pang S, Deng B, Qian L, Chen J, Zou J, Zheng J, Yang L, Zhang C, Chen X, Liu Z, Le Y. High glucose induces renal mesangial cell proliferation and fibronectin expression through JNK/NF-κB/NADPH oxidase/ROS pathway, which is inhibited by resveratrol. Int J Biochem Cell Biol 44: 629-638, 2012.
63. Zhang X, Kiechle FL. Review: Glycosphingolipids in health and disease. Ann Clin Lab Sci 34: 3-13, 2004.
64. Zhang Z, Peng H, Chen J, Chen X, Han F, Xu X, He X, Yan N. MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett 583: 2009-2014, 2009.
65. Zhao H, Przybylska M, Wu IH, Zhang J, Siegel C, Komarnitsky S, Yew NS, Cheng SH. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56: 1210-1218, 2007.